2009. CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin. Hematology Meeting Reports (formerly Haematologica Reports). 2, 5 (Jun. 2009). DOI:https://doi.org/10.4081/hmr.v2i5.735.